255
Participants
Start Date
November 30, 2013
Primary Completion Date
May 31, 2017
Study Completion Date
December 31, 2017
ibudilast
Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
Placebo oral capsule
Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
Cornell Medical College, New York
Columbia University Medical Center, New York
Montefiore Medical Center, The Bronx
University at Stony Brook, The State University of New York, Stony Brook
University at Upstate, The State University of New York, Syracuse
University at Buffalo, The State University of New York, Buffalo
University of Rochester, Rochester
University of Pittsburgh, Pittsburgh
University of Virginia Charlottesville, Charlottesville
Emory University, Atlanta
University of Miami Miller School of Medicine, Miami
University of Alabama at Birmingham, Birmingham
Vanderbilt University, Nashville
Ohio State University, Columbus
Cleveland Clinic, Cleveland
University of Cincinnati, Department of Neurology, Cincinnati
Northwestern University, Evanston
Washington University School of Medicine in St Louis, St Louis
University of Kansas Medical Center, Kansas City
University of Texas Southwestern Medical Center, Dallas
University of Colorado Denver, Denver
University of Utah, Salt Lake City
University of California Los Angeles, Los Angeles
University of California Davis, Davis
Oregon Health and Science University, Portland
Swedish Medical Center - Seattle, Seattle
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Lead Sponsor
National Institutes of Health (NIH)
NIH
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
National Multiple Sclerosis Society
OTHER
MediciNova
INDUSTRY